Zeta EMA Antibody. Zeta’s mouse monoclonal antibody recognizes EMA, a glycoprotein that provides a protective layer on epithelial cells against bacterial and enzyme attacks that can act as a marker for carcinomas. The EMA antibody recognizes proteins ranging from 265-400kDa identified as different glycoforms of EMA. EMA may provide a protective layer on epithelial cells against bacterial and enzyme attacks.
In immunohistochemical assays, Zeta’s EMA antibody superbly stains routine formalin/paraffin carcinomas. The EMA antibody is a valuable marker for staining many carcinomas, staining normal and neoplastic cells from various tissues, including mammary epithelium, sweat glands, and colorectal carcinoma. Hepatocellular carcinoma, adrenal carcinoma, and embryonal carcinomas are consistently EMA negative. As a result, keratin positivity with negative EMA favors one of these tumors. EMA is frequently positive in meningioma, which can be helpful when distinguishing it from other intracranial neoplasms such as schwannomas. The EMAantibody is helpful as a pan-epithelial marker for detecting early metastatic loci of carcinoma in bone marrow or liver.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.